McDermott Represents Arix Bioscience as IP Counsel in $58M VelosBio Investment

McDermott Will & Emery represented Arix Bioscience, a venture capital firm, as intellectual property counsel in a $58 million Series A investment round for VelosBio, a cancer drug developer specializing in antibody drug conjugates, a new class of highly potent drugs which only target cancer cells so that the healthy cells are less affected. Arix Bioscience was the lead investor in a consortium that included Sofinnova Ventures and Pappas Ventures. The McDermott team handled IP issues and licensing due diligence, license negotiations and IP matters at closing.

The McDermott team included Kristina Bieker-Brady, PhD, Suzanne Nguyen, PhD and Kevin Ni, PhD.